Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine

Leukemia Research

Volumn 31, Issue 3, 2007, Pages 407-409

  Kuendgen, A ^a   Graf T ^a   Zohren, F ^a   Hildebrandt, B ^a   Hunerliturkoglu A ^a   Gattermann, N ^a   Haas, R ^a   Kobbe, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Azacytidine; Demethylating drugs; Epigenetic treatment; Refractory leukemia

Indexed keywords

AMSACRINE; AZACITIDINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DOSE RESPONSE; FEMALE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, MYELOID; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION;

EID: 33846057945     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.017     Document Type: Article

References (12)

1. Champlin R., and Gale R.P. Acute myelogenous leukemia: recent advances in therapy. Blood 69 (1987) 1551-1562
2. Kebriaei P., Kline J., Stock W., Kasza K., Le Beau M.M., Larson R.A., et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 35 (2005) 965-970
3. Song K.W., and Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 36 (2005) 183-191
4. Sorm F., Piskala A., Cihak A., and Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20 (1964) 202-203
5. Goffin J., and Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 13 (2002) 1699-1716
6. Glover A.B., Leyland-Jones B.R., Chun H.G., Davies B., and Hoth D.F. Azacitidine: 10 years later. Cancer Treat Rep 71 (1987) 737-746
7. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
8. Silverman L.R., Holland J.F., Weinberg R.S., Alter B.P., Davis R.B., Ellison R.R., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 Suppl. 1 (1993) 21-29
9. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11 (2005) 3604-3608
10. Shadduck R.K., Rossetti J.M., Faroun Y., Kaplan R.B., and Lister J. AML induction therapy with outpatient azacitidine. Blood 104 November (11) (2004)
11. Jani C.R., Pechet L., Ballen K.K., O'Donnel J., and Becker P.S. 5-Azacytidine treatment of patients with myelodysplastic syndrome results in resolution of red cell transfusion dependence for some patients, and for one patient with transformed AML (t-AML) elimination of marrow blasts for nearly 2 years. Blood 98 (2001) 272b
12. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 (2000) 956-962